FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant’s Biz Strategy

Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this once-daily pill designed to block JAK1 and TYK2 proteins is also in clinical development for three additional rare immunological disorders, each with blockbuster potential. The post FDA Nod for Inflammation Drug Notches…

Read More

Why Older Pedestrians Fare Worse in Car Crashes

On an August morning two years ago, Meredith Melville was crossing Piedmont Avenue in Oakland, California, to meet a friend at a cafe. While in the crosswalk, she noticed a car some distance away. Perhaps she misjudged its speed, she said, because she’d walked only partway across the street when the car, a Toyota sedan,…

Read More